ÂÜÀòÂÒÂ×

Oliver Stauch, PhD, is the Chief Operating Officer at Eyconis, Inc. since January 2024, following a significant tenure at Ascendis Pharma from August 2017 to January 2024, where Oliver served as Head of Ophthalmology and VP, Head Product Development (US). In addition to experience at Atropos Therapeutics Inc. as an Advisory Board Member, Oliver has held various influential roles at Genentech between 2013 and 2017, leading efforts in operational excellence, research teams in ophthalmology drug delivery, and managing biological drug product processing. Prior to that, Oliver played key roles at Roche from 2003 to 2013, focusing on biologics R&D and formulation. With a foundational entrepreneurial experience as the founder of Fluids, Oliver also possesses extensive educational credentials, including a PhD in Pharmacy from The University of Freiburg and advanced business training from Stanford University and London Business School.